Overview
QurAlis Corporation: Neuro Pioneers on a Quest to Cure
At QurAlis, we consider ourselves “neuro pioneers” because we are driven to explore the deepest aspects of human neurology in order to find the treatments patients urgently need. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases.
Recent major scientific discoveries, such as disease-causing genetic alterations or the link between STATHMIN-2 and TDP-43, show that different disease drivers cause the development of ALS. Like cancer, these disease mechanisms need to be treated with precision therapies.
QurAlis was founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University to leverage these emerging insights and new technologies. QurAlis co-founder Kevin Eggan, Ph.D., at Harvard pioneered the technology to develop neuronal models derived from patients which resulted in the identification of the genetic targets Kv7.2 and STATHMIN-2 for sporadic ALS. QurAlis has harnessed this founding patient-derived stem cell technology and these breakthrough genetic insights into pre-mRNA regulation of Kv7.2 and STATHMIN-2 together with its unique FlexASO™ splice modulator and QR43™ biology platforms to develop targeted therapies for sporadic ALS and FTD patients.
QurAlis is advancing a robust pipeline with therapeutic candidates that target specific components of disease pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. With three pioneering precision medicine programs, two of which are clinical stage, QurAlis is the leading precision medicine company in the space, providing much-needed hope for people with ALS and FTD as well as for patients suffering from other serious neurodegenerative diseases.
QurAlis is breaking through the barriers of science in our quest to bring much-needed precision therapies to patients.